{
    "nct_id": "NCT06305754",
    "official_title": "A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade <1 or baseline.\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.\n* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.\n* Life expectancy of at least 3 months.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Predominantly squamous cell histology NSCLC.\n* History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.\n* Grade >2 peripheral neuropathy.\n* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.\n* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.\n* Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n* Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention.\n* Known active central nervous system metastases and/or carcinomatous meningitis.\n* Active infection requiring systemic therapy.\n* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.\n* Concurrent active HBV and HCV infection.\n* History of allogeneic tissue/solid organ transplant.\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications.",
    "miscellaneous_criteria": ""
}